Dear Sir,
Although Barlow et al. 1 are right that estimates of analytical performance characteristics in external quality assessment schemes (EQAS) may not reflect those attained in practice, their contribution on faecal occult blood tests (FOBTs) contains some flaws.
Firstly, their description of 'the NHS Bowel Cancer Screening Programme' is inaccurate: it is applicable only to England. Health is a devolved matter and the four countries of the UK have different approaches. The Scottish Bowel Screening Programme began in 2007 and is now fully rolled out, inviting all 50-74 y olds biennially using a two-tier reflex strategy. 2, 3 Secondly, their experiment to determine 'sensitivity', i.e. the analytical detection limit (ADL) is flawed. Their basic assumption is that an 'occult blood-negative' sample contains no peroxidase activity (expressed as mg Hb/g material, not mg/Hb/g). Testing as negative with hema-screen FOBT (Alpha Labs Ltd, Eastleigh, Hants, UK) does not mean that there is no such material present: it simply shows that the concentration is below the ADL. Thus, if material with x mg Hb/g was added to a base sample with any material present, but with concentration less than the ADL, the final concentration would not simply be x mg Hb/g as assumed, 1 but lower. Thus, the true ADL for hema-screen must be less than the 0.7 mg Hb/g suggested. 1 Indeed, for a dichotomous test such as FOBT, the ADL is not the lowest concentration that gives a positive result 100% of the time but that which gives 50% negative and 50% positive results. This is superbly demonstrated in the Yorkshire External Quality Assessment Scheme. For each challenge, the percentages of positive and negative results found are reported. The challenge of 9 November 2009, with 1.2 mg Hb/g matrix, had 17.2% negative and 82.8% positive results. In contrast, the challenge of 21 December 2009, with 0.2 mg Hb/g matrix, had 83.6% negative and 16.4% positive results. If over a range of concentrations, the percentage positive was plotted on the ordinate against concentration on the abscissa, the resulting relationship would rise: if the percentage negative was similarly plotted, the relationship would fall. The concentration at which the relationships intersect is the true ADL. For hema-screen, using this objective approach, 4 the ADL is 0.6 mg Hb/g and not 0.7 mg Hb/g as suggested. 1 Thirdly, it was stated 1 that 'while newer, more specific and more sensitive immunoassays are becoming available, these are more expensive so that the conventional colorimetric tests will remain for some time'. Guaiac-based FOBT have so many disadvantages that they should now be considered obsolete. 5 Newer faecal immunochemical tests (FITs) are specific for intact haemoglobin and its early degradation products and have many advantages. 5 They are not subject to interference from dietary constituents, are clinically more specific for bleeding in the colon and rectum, require less than the two samples from three stools needed for FOBT and generally have more userfriendly collection devices. They are used in many modern screening programmes and advocated in many guidelines. Although important, cost should not be the overriding consideration in selection of laboratory tests.
Fourthly, the only evidence for use of FOBT is in screening programmes. 5 No evidence-based guideline on investigation of lower gastrointestinal tract disorders advocates use of FOBT. Moreover, there are significant welldocumented preanalytical problems in the collection, transport and handling of samples for FOBT. 5 A number of laboratories in the UK have already eliminated FOBT from their repertoires 6 and have actively discouraged use of FOBT in wards, clinics and primary care. I strongly suggest that the laboratory community follow these laudable examples. Then, of course, concerns about poor performance in EQAS would not exist and time and resources would not be wasted undertaking inconclusive studies. In the few clinical situations in which investigation for the presence of blood in faeces would possibly be helpful, including the detection of human faecal blood in the paediatric setting, investigation of symptomatic individuals when bowel visualization is difficult or impossible, follow-up of those with established disease, and in the investigation of familial colorectal cancer, I strongly suggest that FIT should be used. 
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Problems with 'The problems with the investigation of a problem with faecal occult blood tests'
Dear Sir,
We would like to respond to Fraser's letter regarding our recent publication. 1 Fraser is correct in highlighting that health is a devolved matter in the UK. Therefore, in the paper, we should have specifically referred to bowel cancer screening in England rather than the UK. However, in the context of the article the point is largely irrelevant; as all such programmes are funded by the NHS.
He describes our experiment to assess analytical sensitivity/analytical detection limit (ADL) as being flawed. While he is correct in highlighting that 'occult bloodnegative' does not mean that there is no such material present, his critique of our experiment and its' conclusions is confused and mathematically incorrect.
Consider, for example, that the 'base' sample contained an equivalent of 0.2 mg Hb/g matrix. If one then adds a spike of 0.4 mg Hb/g matrix to that material, giving a concentration equivalent to 0.6 mg Hb/g matrix then an assay system with claimed detection limit of 0.6 mg Hb/g matrix (i.e. hema-screen FOBT, Immunostics Inc, Sunset Avenue, Ocean, NJ, USA) should become positive at that concentration. Instead, in our experiment, the test only became positive when we had supplemented the base sample with an additional 0.7 mg Hb/g matrix, which would therefore mean the matrix contained 0.9 mg Hb/g. Therefore our observed 'sensitivity'/ADL of 0.7 mg Hb/g matrix is an optimistic one and the 'true' limit of detection could be even higher than we suggest, and not lower as Fraser implies. Importantly the NHS purchasing and supply agency in their evidence-based purchasing report, also observed a limit of detection of 0.9 mg Hb/g matrix. 2 Fraser argues that a dichotomous test should only be positive at the detection limit 50% of the time and suggests that over a range of concentrations of haemoglobin in samples circulated by the Yorkshire External Quality Assessment Scheme (YEQAS) that the percentage positives and negatives when plotted on the ordinate against concentration on the abscissa will demonstrate an intersection point at a concentration equivalent to the ADL. This makes the invalid assumption that the 17.2% of participants unable to detect a challenge of 1.2 mg Hb/g matrix in the YEQAS faecal occult blood (FOB) scheme are unable to do so simply because of analytical variability. Alternative explanations for these false-negatives may include storage/stability problems, internal quality control problems or training issues. Fraser fails to appreciate this and uses the data to legitimize the manufacturers' claimed detection limit.
Fundamentally, he seems to have missed the entire point of our publication -i.e. to verify that our reporting and interpretations of the occult blood test were robust and reliable; and our experiment proves that irrefutably.
We agree with him that cost should not be an overriding consideration or justification in selection of any methods used in clinical laboratories. However, it is noteworthy that of 182 users registered on the YEQAS only six (3.3%) seem to use an immunological-based occult blood method (2009 data), illustrating the budgetary constraints that may prevent laboratories migrating to a significantly more expensive immunochemical assay.
Lastly, Fraser restates his personal opinion 3 that FOB testing, outside of a bowel cancer screening programme should be abandoned. While that opinion might not be shared by all, as 182 users/laboratories continue their participation in the YEQAS programme, presumably undertaking occult blood testing out with screening programmes, the highlighting of this issue does serve as a timely reminder for laboratories to reconsider their position.
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